The federal drug pricing program 340B helps hospitals and clinics in Virginia and across the nation care for underserved patients by requiring pharmaceutical companies to offer prescription discounts ...

A fight over an embattled drug discount program is intensifying on Capitol Hill, as lawmakers weigh competing proposals to ...

Hospital drug markups are in the crosshairs as a new proposal targets 340B facilities where a $700 prostate cancer treatment ...

Henry Ford Health has filed a lawsuit against CVS Health (NYSE:CVS) alleging fraudulent reimbursement practices tied to the ...

It's the latest evidence of rising spending in the drug discount program as regulators attempt to tamp down on growth in 340B.

Forbes contributors publish independent expert analyses and insights. Anthony T. Lo Sasso is Professor of Public Affairs at UW-Madison This voice experience is generated by AI. Learn more. This voice ...

The high list prices of gene therapies command the media’s attention and that of policymakers and payers. Late last year, the Food and Drug Administration (FDA) approved the world’s first gene therapy ...

Outpatient drug purchases under the 340B Drug Pricing Program crossed the $100 billion mark across 2025, a roughly 23% ...

Amid ongoing controversy over 340B drug discounts, a sweeping review suggests the program is doing what it was intended to do: generate revenue for hospitals, clinics and pharmacies by requiring ...

In almost exactly one year, if no action is taken by the Minnesota legislature, hospitals across the state of Minnesota will ...

Institutions that are not genuinely serving the underserved should not collect 340B discounts, and the loopholes that reward ...

For decades, I worked in Maine’s operating rooms and hospital wards as a neurosurgeon. My career took me from the bustling ...